| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.9 |
| mRNA | Methotrexate | FIMM | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.026 | 0.9 |
| mRNA | BRD-K44224150 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.9 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |